7 citations,
April 2021 in “British Journal of Dermatology” Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.
6 citations,
June 2016 in “Experimental Dermatology” Frontal Fibrosing Alopecia is a poorly understood condition that is hard to treat and causes distressing hair loss.
[object Object] 2 citations,
June 2018 in “Journal of the American Academy of Dermatology” Alopecia areata causes varying hair loss and nail changes, and treatments include topical, systemic, and injectable therapies.
2 citations,
November 2014 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.
1 citations,
June 2018 in “International Journal of Dermatology” DNCB is highly effective for treating alopecia areata with minimal long-term side effects.
January 2024 in “Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica/Revista de la Asociacion Colombiana de Dermatologia y Cirugia Dermatologica” Baricitinib successfully treated severe hair loss.
October 2023 in “International journal of rheumatic diseases” New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
[object Object] January 2018 in “Journal of the American Academy of Dermatology” Combining pulsed prednisone with tofacitinib can lead to lasting hair regrowth in severe alopecia areata patients.
70 citations,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
39 citations,
April 2016 in “Case Reports in Dermatology” Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
37 citations,
May 2016 in “Deutsches Arzteblatt International” Hair loss requires customized treatments based on its various causes and types.
28 citations,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
24 citations,
June 2016 in “Acta dermato-venereologica” Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.
17 citations,
August 2015 in “Expert Opinion on Pharmacotherapy” The document concludes that oral finasteride and topical minoxidil are effective for genetic hair loss, while other treatments for different types of hair loss show promise but need more research.
16 citations,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
13 citations,
February 2019 in “Journal of the American Academy of Dermatology” The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
3 citations,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
2 citations,
May 2017 in “InTech eBooks” Stem cells could improve hair growth and new treatments for baldness are being researched.
1 citations,
June 2017 in “Journal of the American Academy of Dermatology” Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
November 2020 in “Dubai medical journal” Tofacitinib may effectively regrow hair in alopecia totalis patients.
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
20 citations,
January 2017 in “Actas Dermo-Sifiliográficas” Recent advances in hair loss treatments show significant progress.
7 citations,
March 2017 in “Actas Dermo-Sifiliográficas” Several new treatments for different types of hair loss show promise in improving patient quality of life.
5 citations,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
March 2024 in “Dermatology and therapy” AA patients with comorbid conditions face more severe hair loss and need specific treatments.
June 2023 in “Dermatology and therapy” Doctors in the Middle East need better treatments and more knowledge about new therapies for hair loss condition Alopecia Areata.
701 citations,
August 2014 in “Nature medicine” Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
2 citations,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
January 2025 in “Frontiers in Pediatrics” Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.